Abstract 448P
Background
Chemotherapy efficacy depends on relative dose intensity (RDI) and an RDI <85% is associated with unfavourable overall survival. Clinicopathological characteristics have been observed as risk factors of reduced RDI. The pro-inflammatory markers such as interleukin-6 (IL-6) and C-reactive protein (CRP), which also serve as biomarkers of aging, have been reported to associate with RDI. We aimed to determine whether these parameters have influence on RDI in the local breast cancer (BC) patients.
Methods
This cross-sectional study recruited 172 women with stage I-IV BC receiving first-line chemotherapy between July 2018-March 2022. Sociodemographic, clinicopathological, and treatment data and peripheral blood samples were collected prior to chemotherapy. IL-6 and CRP levels were analyzed using quantitative ELISA. Dose reductions and delays were captured and utilized to calculate the patient’s RDI. Multivariable logistic regression analysis was performed to determine the association between pre-chemotherapy parameters and RDI <85%.
Results
Mean age was 52 years (range 32-78). The average RDI for all patients was 93% and an RDI <85% occurred in 23 (13.4%) patients. Mean IL-6 level was 1.12 pg/ml (range 0.0–27.7) and mean CRP was 10.82 μg/ml (range 0.0–151.7). Factors associated with reduced RDI were diabetes mellitus comorbidity (OR 5.13, 95% CI 1.38–19.03; p =0.015), triple-negative tumours (OR 4.17, 95% CI 1.09–15.89; p =0.037), palliative treatment setting (OR 3.75, 95% CI 1.12–12.62, p =0.032), and IL-6 serum level >0.485 pg/ml (OR 3.46, 95% CI 1.05–11.37; p =0.041).
Conclusions
The presence of diabetes mellitus comorbidity, triple-negative tumours, palliative treatment intention, and IL-6 serum level >0.485 pg/ml are associated with reduced RDI. Further investigation is warranted to confirm the association between biomarker of aging and chemotherapy delivery.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Faculty of Medicine, Public Health and Nursing, Gadjah Mada University, The Ministry of Education, Culture, Research, and Technology.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
193P - Impact of coronavirus disease 2019 on patients with unresectable hepatocellular carcinoma treated with atezolizumab/bevacizumab
Presenter: Hongjae Chon
Session: Poster Display
Resources:
Abstract
194P - Real-world outcomes of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus chemotherapy as first-line treatment in advanced gastric (G) or gastroesophageal junction (GEJ) cancer with PD-L1 CPS≤5
Presenter: Qi Xu
Session: Poster Display
Resources:
Abstract
195P - Ferroptosis signatures in pancreatic ductal adenocarcinomas and their role in patient survival: A translational unsupervised clustering analysis
Presenter: Quoc-Huy Trinh
Session: Poster Display
Resources:
Abstract
196P - Clinical significance of circulating CD8+ and CD4+ T cell proliferation in advanced gastric cancer receiving first-line chemotherapy
Presenter: In-Ho Kim
Session: Poster Display
Resources:
Abstract
197P - Treatment patterns and clinical outcomes of patients with unresectable advanced or metastatic (UAM) gastric/gastroesophageal junction adenocarcinoma (GA/GEJA) in China: A multicenter real-world study
Presenter: Yanqiao Zhang
Session: Poster Display
Resources:
Abstract
198P - Effectiveness of lenvatinib in patients with unresectable hepatocellular carcinoma: A multicenter observational study in Japan
Presenter: Namiki Izumi
Session: Poster Display
Resources:
Abstract
199P - Efficacy of endostar in combination with concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of esophagus: A randomized, open-label, phase II trial
Presenter: Yuexiao Qi
Session: Poster Display
Resources:
Abstract
200P - Prognosis of patients with hepatocellular carcinoma treated with transarterial chemoembolization: Development and validation of the ALFP score
Presenter: Baocuo Gong
Session: Poster Display
Resources:
Abstract
201P - A phase II study of serplulimab (a programmed death-1 inhibitor) with or without HLX04 (a bevacizumab biosimilar) for the treatment of advanced hepatocellular carcinoma
Presenter: Zhenggang Ren
Session: Poster Display
Resources:
Abstract
202P - Comparison of liver injury after transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy for intermediate and advanced hepatocellular carcinoma
Presenter: Yongru Chen
Session: Poster Display
Resources:
Abstract